TuHURA Biosciences, Inc. (NasdaqCM: HURA)
Health Care · Biotechnology · US
$1.93
+1.05% today · -23.3% 1Y
TuHURA Biosciences, Inc. (NasdaqCM: HURA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $121.72M and employs 22 people.
Over the last twelve months the share price has lost 23.3%, trading between 0.41 and 3.43.
Tweenvest scores TuHURA Biosciences, Inc. across four factors: quality 33/100, value 43/100. Its strongest factor is value.
HURA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $121.72M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.54
- Dividend yield
- —
- Beta (5Y)
- -0.84
- 52-week high
- $3.43
- 52-week low
- $0.41
- Avg volume (3M)
- —
- Shares outstanding
- 63.73M
- Employees
- 22
- Next earnings
- —
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
- ISIN
- US8989201038
- Founded
- 1995
- Listed since
- Feb 22, 2013
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Humacyte, Inc.NasdaqGS: HUMA | $124.20M | $0.45 | -5.34% |
| Sunho Biologics, Inc.SEHK: 2898 | $123.78M | HK$— | — |
| Heidelberg Pharma AGXTRA: HPHA | $123.74M | €2.35 | -8.91% |
| StemCyte International, Ltd.TWSE: 4178 | $121.98M | NT$18.00 | +9.09% |
| Pharmosa Biopharm Inc.TPEX: 6875 | $121.25M | NT$29.90 | -6.12% |
| Bioventix PLCAIM: BVXP | $120.83M | £17.50 | 0.00% |
| Foghorn Therapeutics Inc.NasdaqGM: FHTX | $119.96M | $1.99 | -1.49% |
| Corbus Pharmaceuticals Holdings, Inc.NasdaqCM: CRBP | $118.56M | $5.27 | -14.03% |
Figures last refreshed Oct 4, 2026.